Mimetas

The page describes a 3D lung tumor-on-a-chip model evaluating T-cell migration, endothelial interactions and therapeutic modulation under immunotherapy conditions.

MIMETAS offers OrganoPlate, OrganoTEER and OrganoFlow for 3D tissue culture and experimentation.

This endothelium-on-a-chip assay enables RT analysis of T-cell extravasation and trafficking under inflammation and cancer-mimicking conditions.

The page describes OrganoPlate formats: 2-lane 96, 3-lane 40, 3-lane 64 and Graft.

The page describes a human BBB-on-a-chip model with barrier dysfunction and T cell migration for drug discovery in neuroinflammatory and CNS diseases.

The page describes a vascular inflammation-on-a-chip model combining TEER and immune cell migration studies for drug screening of endothelial dysfunction.

The company held its annual 3D-cember 2020 event as its first live-streamed edition and shared videos of the APAC and EU-US streams for on-demand viewing.

Leiden, January 5, 2023 - Scientists from MIMETAS and the University of Texas Health Center develop a model system that supports the culture of clinically relevant PDX cells that recapitulate aspects of the prostate cancer (PCa) tumor microenvironment (TME).

Leiden, August 2, 2021 – Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throughput, artificial membrane-free microfluidic platform. The research has just been published in the International Journal of Molecular Sciences.

Leiden, February 3, 2023 – MIMETAS scientists established a 3D Pancreatic Ductal Adenocarcinoma (PDAC) model, enabling the study of cancer treatment response in PDAC organoids.

The page discusses organ-on-a-chip technology and 3D human tissue models for therapeutic efficacy and preclinical testing reliability.

MIMETAS discusses advanced tissue models for research through a contact form or by phone.

MIMETAS's organ-on-a-chip platform provides human tissue models for drug discovery and is described as reducing risks and ethical concerns.

The page sets out Mimetas B.V.'s general terms and conditions for delivery, purchase, and use.

MIMETAS contributes human organ-on-chip data from its OrganoPlate platform to support argenx’s Investigational New Drug (IND) application. The contribution aligns with the 2022 FDA Modernization Act 2.0.

Jul 2024BioTech NewswireNews article

MIMETAS and Astellas expand their March 2023 immuno-oncology partnership to include automation and application support. The expanded support is built on MIMETAS' comprehensive tumor models.

Jun 2023BioTech NewswireNews article

MIMETAS and Roche collaborate to develop human disease models for inflammatory bowel disease and hepatitis B on the OrganoPlate platform. The agreement includes upfront and milestone payments to MIMETAS.

Jul 2021B3C NewswireNews article

MIMETAS launches its Assay Ready product line with the OrganoPlate Caco-2 intestinal tubule model. The line delivers ready-to-use tissue models for ADME, safety, and toxicology studies.

Mar 2020BioSpaceNews article